BridgeBio Oncology Therapeutics Inc. Ordinary Shares - Class A BBOT 深 沪
等待开盘 11-04 09:30:00 美东时间
12.29
+0.350
+2.93%
华盛通- 最 高12.37
- 今 开11.96
- 成交量 16.01万股
- 最 低 11.88
- 昨 收 11.94
- 总市值 9.73亿
- 52周最高 13.18
- 市盈率 静 38.01
- 换手率 0.20%
- 52周最低 8.50
- 委 比 -79.10%
- 总股本 7919.67万
- 历史最高 13.18
- 量 比 1.21
- 振 幅 4.10%
- 历史最低 8.50
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
BBO-10203, a first-in-class RAS:PI3Kα interaction breaker, selectively inhibits RAS-mediated PI3Kα-AKT signaling in tumors without causing hyperglycemia. Preclinical data show robust anti-tumor activity as monotherapy and in combination with BBOT's KRAS inhibitors, BBO-8520 and BBO-11818, across KRAS-mutant models. The drug is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ breast cancer, HR+/HER2- breast cancer...
10-25 16:30
BridgeBio Presents New Preclinical Data On BBO-11818 Demonstrating Potential As Potent panKRAS Inhibitor Targeting Mutant KRAS In Both ON And OFF States, With Selectivity Over HRAS And NRAS, At 2025 AACR-NCI-EORTC
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) models BBO-11818's
10-24 04:13
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BBO-11818是一种新型的panKRAS抑制剂，瞄准KRAS基因突变，包括G12D和G12V。临床前数据显示其有效抑制MAPK信号和细胞增殖，并在多个 KRAS突变的异种移植模型中显示抗肿瘤活性。不同于只能针对G12C突变的现有药物，BBO-11818对HRAS和NRAS的选择性高，具有良好的安全性。它还与BBOT的其他药物如BBO-10203和cetuximab联用时显示出增强的疗效。目前，BBO-11818正在胰腺癌、非小细胞肺癌和结直肠癌患者中进行I期临床试验，预计2026年下半年公布初步数据。
10-23 20:05
Bridgebio Oncology Therapeutics Announces It Will Present Posters At The 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics October 22–26, 2025, In Boston, Massachusetts
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International
10-14 04:09
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The conference will feature two abstracts: BBO-11818, a pan-KRAS inhibitor, presented by Carlos Stahlhut, PhD on October 23; and BBO-10203, a RAS:PI3Kα interaction breaker, presented by Kerstin Sinkevicius, PhD on October 25. BBOT focuses on developing novel small m...
10-13 20:05
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
HC Wainwright & Co. Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $27
HC Wainwright & Co. analyst Robert Burns initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $27.
09-15 19:58
Oppenheimer Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $23
Oppenheimer analyst Matthew Biegler initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $23.
09-04 20:52
BBOT to Participate in Upcoming September Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced that members of its leadership team will participate in two investor conferences in September: the Cantor Global Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 8. Both events will include Fireside Chats and investor meetings in New York. Live webcasts and replays will be available on the "Investors" page of the BBOT website, with replays access...
08-20 12:00
